Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus standard endocrine therapy in HR-positive, HER2-negative advanced breast cancer
ChiCTR2200060315Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: progression-free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200060315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060315.